Sirana Enters Research Collaboration Agreement With Pfizer Over Bone Disease

Sirana Pharma inked a research collaboration deal with Pfizer to investigate a novel treatment concept for an unnamed rare bone disease.

The collaboration will involve the use of Sirana’s proprietary microRNA (miRNA)-targeting approach, which involves regenerative recovery of diseased muscle and bone tissue. Sirana is also developing molecules to treat Sarcopenia, age-related muscle weakness, and Osteogenesis imperfecta, an inherited brittle bone disease.

“We look forward to working together with the Sirana team to further explore this new and innovative investigational approach,” said Seng H. Cheng, Pfizer’s chief scientific officer for rare diseases.

The financial terms of the collaboration were not disclosed.